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Abstract
Introduction: A recent study reported an association between inactivated influenza vaccine (IIV) 
and spontaneous abortion (SAB), but only among women who had also been vaccinated in the 
previous influenza season. We sought to estimate the association between IIV administered in 
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three recent influenza seasons and SAB among women who were and were not vaccinated in the 
previous influenza season.
Methods: We conducted a case-control study over three influenza seasons (2012–13, 2013–14, 
2014–15) in the Vaccine Safety Datalink (VSD). Cases (women with SAB) and controls (women 
with live births) were matched on VSD site, date of last menstrual period, age group, and influenza 
vaccination status in the previous influenza season. Of 1908 presumptive cases identified from the 
electronic record, 1236 were included in the main analysis. Administration of IIV was documented 
in several risk windows, including 1–28, 29–56, and >56 days before the SAB date.
Results: Among 627 matched pairs vaccinated in the previous season, no association was found 
between vaccination in the 1–28 day risk window and SAB (adjusted odds ratio (aOR) 0.9; 95% 
confidence interval (CI) 0.6–1.5). The season-specific aOR ranged from 0.5 to 1.7 with all CIs 
including the null value of 1.0. Similarly, no association was found among women who were not 
vaccinated in the previous season; the season-specific aOR in the 1–28 day risk window ranged 
from 0.6 to 0.7 and the 95% CI included 1.0 in each season. There was no association found 
between SAB and influenza vaccination in the other risk windows, or when vaccine receipt was 
analyzed relative to date of conception.
Conclusion: During these seasons we found no association between IIV and SAB, including 
among women vaccinated in the previous season. These findings lend support to current 
recommendations for influenza vaccination at any time during pregnancy, including the first 
trimester.
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1. Introduction
Influenza infection can cause serious complications, especially in high-risk persons, which 
include pregnant women [1,2]. Studies show that pregnant women experience higher rates of 
morbidity, hospitalization, and mortality during seasonal influenza epidemics and 
pandemics, such as the 2009 pandemic caused by A/California/7/2009 (H1N1)pdm09 
(pH1N1) [3–6]. Since 2004, the Centers for Disease Control and Prevention (CDC) 
Advisory Committee on Immunization Practices (ACIP) and other organizations have 
recommended vaccination of women who are or will be in any stage of pregnancy during the 
influenza season [7,8]. Numerous studies have established the safety of seasonal influenza 
vaccines administered to pregnant women [9–11]; particularly relevant for this study are the 
safety studies of vaccines containing pH1N1 antigens and the risk of spontaneous abortion 
[12–18].
In 2017, Vaccine Safety Datalink (VSD) investigators published a case-control study that 
reported an adjusted odds ratio (aOR) of 2.0 and a 95% confidence interval (CI) of 1.1 to 3.6 
for spontaneous abortion (SAB) among women vaccinated with inactivated influenza 
vaccination (IIV) [19]. Post hoc analyses revealed that in each of the two influenza seasons 
studied (2010–11 and 2011–12), the association between IIV and SAB was found only in 
women vaccinated in the 1–28 days before the SAB who had also received a pH1N1-
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containing influenza vaccine the previous season (i.e., effect modification). Although the 
results were based on relatively small sample sizes, additional investigation did not identify 
any error or bias that might explain these findings. This study was preceded by a similarly 
designed VSD study of women pregnant in the influenza seasons of 2005–06 and 2006–07 
that observed an aOR of 1.2 (95% CI 0.5–2.9) for the IIV-SAB association in the 128 day 
risk window [20]. However, the earlier study did not evaluate vaccination in the previous 
influenza season. Here we report the findings of a third VSD study specifically designed to 
determine if receipt of IIV was associated with SAB among women who had and had not 
been administered influenza vaccine the previous season. For the purposes of this report, we 
refer to the VSD study of women pregnant in the 2005–06 or 2006–07 influenza seasons as 
IIV-SAB-1 [20], the VSD study of women pregnant in the 2010–11 and 2011–12 influenza 
seasons as IIV-SAB-2 [19], and the current VSD study of women pregnant in the 2012–13, 
2013–14, and 2014–15 influenza seasons as IIV-SAB-3.
2. Methods
2.1. Study population
In IIV-SAB-3, we included women who were pregnant during the 2012–13, 2013–14, or 
2014–15 influenza seasons and were members of the VSD population at one of six 
integrated healthcare delivery organizations: Kaiser Permanente (Colorado, Northern 
California, Southern California, Northwest, Washington) and Marshfield Clinic in 
Wisconsin. Sites contributed subjects approximately proportionate to their size in the overall 
VSD population. The VSD was established in 1990 as a collaborative project between 
several integrated healthcare organizations and CDC; it is one of the primary post-licensure 
vaccine safety monitoring and research systems in the United States [21].
The study was approved by the Institutional Review Boards of each VSD organization.
2.2. Cases
We identified possible cases of SAB by searching VSD databases for spontaneous and 
unspecified abortion diagnosis codes (International Classification of Diseases, 9th Revision, 
Clinical Modification (ICD-9-CM) 634.* and 637.* (Supplemental Table 1) assigned during 
encounters in ambulatory, urgent care, emergency department, and inpatient settings. To 
enhance our ability to identify effect modification by previous season influenza vaccination, 
we conducted stratified sampling to ensure 50% of the cases in each of the three seasons 
were vaccinated in the previous influenza season.
The primary analysis focused on cases with gestational ages between 6 and <20 weeks at 
time of estimated pregnancy loss; however, we also examined SABs between 5 and <20 
weeks in a secondary analysis to be consistent with IIV-SAB-2 [19]. We only included SAB 
diagnoses assigned during the influenza season (September 1 through April 28) to avoid 
including women with no opportunity for influenza vaccination. We confirmed pregnancy 
using information abstracted from the medical record: obstetric ultrasound, clinic or 
hospital-based assay (e.g., human chorionic gonadotropin level), patient-reported test, and/or 
physician diagnosis.
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Study eligibility criteria included: (1) documentation of last menstrual period (LMP) in the 
medical record, (2) continuous enrollment in the healthcare organization for 20 months prior 
to the LMP, (3) age 18–44 years on the date of LMP, and (4) SAB confirmed by ultrasound 
or by clinical diagnosis in the absence of ultrasound results. More than 90% of cases had 
ultrasound information available, but ultrasound was not required for eligibility. The 
continuous enrollment requirement was necessary to ensure capture of prior influenza 
vaccinations and chronic medical conditions from the medical record. Exclusion criteria 
included ectopic pregnancy, therapeutic abortion, multi-fetal pregnancy, or SAB occurring at 
<5 weeks’ gestation.
Documentation of all cases began with a search of electronic diagnosis codes and was 
supplemented with available information about care received for their SAB, which was 
obtained from the medical record. We abstracted information related to pregnancy, including 
ultrasound and medical history, from medical records of cases using trained abstractors. All 
potential cases with an ultrasound were adjudicated by the investigative team (blinded to 
influenza vaccination status) to determine the SAB date and gestational age at the time of 
pregnancy loss as accurately as possible following an algorithm that was developed and 
refined by the study obstetrician (M.A.M.).[22] The SAB date was based on the earliest 
clinical diagnosis for women without ultrasound results. The study obstetrician (M.A.M.), 
who was also blinded to vaccination status, adjudicated cases with equivocal ultrasound 
results. We defined the SAB date as the LMP date plus the estimated gestational age at the 
time of the SAB.
2.3. Controls
Controls met the same age, LMP, and enrollment inclusion criteria as cases but had a live 
delivery instead of an SAB diagnosis; live delivery was identified using a VSD pregnancy 
database [23] or by searching for specific ICD-9 or ICD-10 codes in VSD data files 
(Supplemental Table 1). Trained abstractors reviewed medical records to confirm the live 
delivery and collect additional clinical and pregnancy information.
2.4. Matching
We individually matched cases and controls (1:1 ratio) by VSD site, maternal age (18–24, 
25–34, and 35–44 years), influenza vaccination status in the previous season, and LMP. 
While matching multiple controls to each case would have provided methodological 
advantages, a 1:1 ratio was considered optimal given the available resources. Matching on 
vaccination in the previous season increased statistical power to identify effect modification 
by previous season vaccination on the potential association between current-season IIV and 
SAB. Matching on LMP ensured that cases and controls would have similar opportunity for 
influenza vaccination in early pregnancy and nearly identical gestational ages relative to 
calendar time. Matching on LMP began after we identified and adjudicated cases; 10 
potential controls with LMP dates within seven days of the case LMP were randomly 
selected. We selected the first eligible control with an LMP most closely matching the case 
LMP. The estimated SAB date for the case was used as the reference date for each case-
control pair.
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2.5. Influenza vaccine exposure
The composition of trivalent IIV for the 2012–13 season was: A/California/7/2009 (H1N1)-
like, A/Victoria/361/2011 (H3N2)-like, and B/Wisconsin/1/2010-like (Yamagata lineage).
[24] The composition of trivalent IIV for the 2013–14 and 2014–15 seasons was: A/
California/7/2009 (H1N1)-like virus, A/Texas/50/2012 (H3N2)-like virus, and B/
Massachusetts/2/2012-like (Yamagata lineage) virus. The quadrivalent IIVs for the 2013–14 
and 2014–15 seasons contained the above antigens and B/Brisbane/60/2008-like (Victoria 
lineage) virus [25,26]. However, less than 3% of IIV administered to our study population 
was quadrivalent; therefore, we did not differentiate trivalent and quadrivalent IIV exposures 
in the analysis.
We abstracted vaccination dates for influenza and other vaccines administered during 
pregnancy from medical records. Vaccines administered between August 1 and June 30 in 
the influenza season where the SAB for the matched pair occurred were considered current-
season vaccinations. Women were considered exposed only if the vaccine was administered 
before the reference date; we classified women receiving influenza vaccines on or after the 
reference date as unexposed in all analyses. For analyses examining the association of SAB 
and vaccinations relative to the reference date, we categorized current-season vaccinations 
into three mutually exclusive risk windows that preceded the reference date: 128, 29–56, and 
>56 days. For analyses examining the association of SAB and vaccinations relative to 
conception, current-season vaccinations were categorized into four risk windows relative to 
conception date: >42 days before, 0–42 days before, 1–28 days after (and before the 
reference date), and >28 days after (and before the reference date). Conception was defined 
as the date of the last menstrual period plus 14 days. We also documented influenza vaccines 
administered to women during the influenza season before the season in which the SAB for 
the matched pair occurred. We excluded matched pairs containing 22 women who were 
administered LAIV or high-dose IIV before the reference date in the current season. Valid 
previous season vaccinations included all vaccine types, except high-dose IIV.
2.6. Statistical analysis
We compared characteristics of matched cases and controls using Wilcoxon signed-rank 
tests for continuous variables, [27] McNemar tests for dichotomous variables, [28] and 
Bowkef’s test of symmetry for categorical variables with more than two levels [29]. P-values 
were based on two-sided tests. We used SAS 9.4 (SAS Institute, Cary, NC) for the analysis.
We performed conditional logistic regression to estimate the association between receipt of 
IIV and SAB. We decided a priori to build separate models (including separate confounding 
assessments) for women vaccinated in the previous influenza season and those that were not 
to facilitate assessment of effect modification. We built a third model using the pooled data 
from the above two strata after finding no statistical evidence of effect modification by 
previous season vaccination status.
We included three covariates in all multivariable models because they were suspected a 
priori to be associated with both SAB and vaccination: maternal age, pre-pregnancy body 
mass index (BMI), and previous healthcare utilization (defined as the number of days with at 
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least one healthcare encounter (inpatient or outpatient) in the year before the LMP) [30]. We 
assessed other covariates based on associations observed between the covariate and the 
outcome (i.e., SAB) and included those with P-values ≤0.20.[31] Variables screened as 
potential confounders appear in Table 1 although some were not viable candidates due to 
sparse data or many missing values. As in the previous two studies, [19,20] we did not adjust 
for history of prior SAB to avoid potential bias [32], although we conducted a secondary 
analysis excluding matched pairs where either woman had a history of ≥2 SABs.
All three models described above included the core covariates: maternal age, pre-pregnancy 
BMI, previous healthcare utilization, Hispanic ethnicity, and four non-mutually-exclusive 
race variables. We entered age, BMI, and resource utilization in the models as natural cubic 
splines [33]. Since age group was a matching factor, rather than a spline for age itself, we 
entered in the models a spline for the deviation of each woman’s age from the mean age in 
their matched pair [34]. In our study population 334 women (13.5%) did not have a specified 
race, and this was strongly linked to Hispanic ethnicity; 92.2% of those with no race 
specified were Hispanic, compared to 18.4% of those with a specified race. Therefore, we 
did not exclude persons from the analysis if race was not specified because we believed that 
such exclusion would introduce bias. However, because retaining these individuals in the 
analysis may also cause bias, we conducted a secondary analysis in which we excluded all 
matched pairs where at least one woman did not have a specified race (n = 315 pairs). The 
model for subjects vaccinated the previous season also included history of type 1 or 2 
diabetes, asthma, and presence of febrile illness in the 14 days before the reference date. The 
model for subjects not vaccinated the previous season included the core covariates and 
parity. Finally, the overall model included all variables in the stratum-specific models plus 
pre-existing hypertension. The referent exposure group in all odds ratio (OR) calculations 
was comprised of women not vaccinated as of the reference date. We structured our power 
calculations on the power to detect an association between IIV and SAB in the 1–128 days 
before the reference date (the primary risk window) for a given influenza season and stratum 
(vaccinated in the previous season or not). We determined that 250 matched pairs per 
stratum per season were required to detect an OR of 3.5 with a power of 0.82 in the primary 
risk window. Pooling stratum-specific data for two seasons (e.g., seasons where the 
influenza vaccine composition was the same) resulted in power of 0.82 to detect an OR of 
2.3. Pooling both strata and all seasons would result in power of 0.83 to detect an OR of 1.6. 
We based power calculations on a proportion of 0.106 for pairs that were discordant for 
current-season vaccination exposure, which was derived from IIV-SAB-2 [19]. Additional 
assumptions used in the power calculations were 1:1 matching of cases and controls and 
two-sided α = 0.05.
3. Results
We identified 1908 presumptive SAB cases from automated data using diagnosis codes (Fig. 
1). Of these, 166 (8.7%) were ineligible due to the absence of LMP or other reasons (e.g., 
unconfirmed pregnancy, multi-fetal pregnancies, LMP outside eligible period, age <18 
years), and an additional 108 (5.7%) had non-SAB outcomes (e.g., therapeutic abortion, 
ectopic pregnancy, live birth). Of 1634 confirmed cases of SAB, we excluded 224 (13.7%) 
after adjudication due to gestational age being out of range, adjudicated SAB date prior to 
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September 1, or other reasons (e.g., therapeutic abortion). Of 1410 eligible and confirmed 
cases of SAB, we were unable to match 29 (2.1%) to an eligible control. The remaining 
1381 cases (72.4% of 1908) had a gestational age of 5-<20 weeks and were matched to 1381 
controls resulting in a total study population of 2762. Of these, 1236 cases (89.5%) had a 
gestational age of 6-<20 weeks and were the focus of the primary analysis.
We compared the demographic and clinical characteristics of cases and controls, stratified by 
previous season vaccination status (Table 1). Of the 1236 matched pairs in the main analysis, 
627 were vaccinated in the previous season and 609 were not. Within each stratum, the 
median maternal age of cases was greater than controls; a larger proportion of cases were 
40–44 years old compared to controls; pre-pregnancy BMI was greater among cases than 
controls; and cases were more likely to be Black/African American, less likely to be Asian, 
and more likely to be Hispanic than controls. Cases and controls were similar with respect to 
parity (≥1) and gravidity (≥1), but both were lower among subjects not vaccinated the 
previous season. The proportion of cases and controls with a history of ≥1 or ≥2 
miscarriages was similar in both strata. Alcohol and smoking exposure during pregnancy did 
not vary by case-control status, but was greater among women not vaccinated the previous 
season. Among women vaccinated the previous season, cases were more likely than controls 
to have a history of diabetes. Asthma and febrile illness in the 1–14 days before the 
reference date were also more common among cases. Other factors were similar in cases and 
controls or were uncommon. Selected characteristics of study subjects showed minimal 
variation by season of enrollment (Supplemental Table 2).
Overall and season-specific proportions of women vaccinated for influenza in the various 
risk windows before the reference date were generally greater among women vaccinated the 
previous season compared to those not vaccinated previously; however, within each stratum 
cases and controls had similar vaccination proportions (Table 2). For example, among cases 
in all seasons who were vaccinated the previous season, 10% (n = 70) were vaccinated in the 
1–28 day risk window compared to 9% (n = 64) of controls.
Among women vaccinated the previous season, the aOR for influenza vaccine receipt in the 
1–28 day risk window was 0.9 (95% CI, 0.6 to 1.5) (Table 3). Season-specific aORs for the 
128 day window ranged from 0.5 to 1.7; the 95% CIs included 1.0 for each season; similar 
results were noted for other risk windows (29–56 and > 56 days). Among women not 
vaccinated the previous season, the overall aOR in the 1–28 day window and season-specific 
aORs were all less than 1.0 with 95% CI that included 1.0. The aORs for other risk windows 
ranged from 0.1 to 1.8 in the three seasons, with 95% CI that included 1.0 in each instance.
Because effect modification of the association of IIV and SAB by vaccination in the 
previous season was not observed, we pooled stratum-specific data to produce aORs for each 
risk window in each season and for all seasons combined. The aORs were less than or close 
to 1.0 in every risk window and season (Table 4).
In the analyses of vaccination relative to conception, aORs for IIV receipt in each risk 
window and for all seasons combined were generally less than or close to 1.0 among women 
who were and were not vaccinated the previous season (Table 5). However, several 
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subgroups had aOR point estimates greater than 1.0, although in each instance the lower 
bound of the 95% CI was less than 1.0. In a combined analysis that included all women, the 
aOR for all seasons combined was less than 1.0 in each risk window (Supplemental Table 3).
We also performed secondary analyses that included all SAB cases with gestational age 5-
<20 weeks (1381 matched pairs) to be consistent with IIV-SAB-2 [19]; the findings were 
similar to the primary analyses (Supplemental Table 4). Analysis of risk windows relative to 
conception also yielded similar results (Supplemental Table 5). In a separate secondary 
analysis that excluded women with a history of >2 prior SABs, the results were largely 
unchanged (Supplemental Tables 6 and 7). Exclusion of the 315 matched pairs where at least 
one woman did not have a specified race showed no meaningful differences compared to the 
primary results (Supplemental Tables 8–10). Nearly all adjusted ORs are less than or close 
to 1.0 and all 95% confidence intervals for aORs above 1.0 include the null.
4. Discussion
We conducted a third matched case-control study of pregnant women in the VSD and found 
no association between IIV and SAB, providing reassurance regarding the safety of IIV in 
pregnancy. CDC and VSD investigators conducted this study to follow up on a safety signal 
for SAB following IIV detected in IIV-SAB-2, which included women who were pregnant in 
the two seasons immediately following the 2009 influenza pandemic (2010–11, 2011–12) 
[19]. The most notable finding from IIV-SAB-2 was an association of SAB in women who 
received IIV in the 1–28 days before the reference date. Subgroup analyses revealed that this 
association was found in both seasons, but only in women who were also vaccinated in the 
previous influenza season. Additional analyses failed to identify sources of confounding or 
bias that could explain the findings. The results of IIV-SAB-2 were unexpected because 
aORs were greater than those observed in IIV-SAB-1, which evaluated IIV and SAB in 
women who were pregnant in 2005–06 and 2006–07 [19,20]. While biologic processes for a 
relationship between IIV and SAB are theoretically possible, no plausible causal pathway 
has been established [35–38].
We designed IIV-SAB-3, which included 1236 matched pairs in the main analysis, to have 
sufficient power to detect an association between IIV and SAB, both for women vaccinated 
the previous season and those not vaccinated the previous season. Among women vaccinated 
the previous season, the aORs across all seasons were <1.0 for all three risk windows 
preceding the reference date, including the 1–28 day window. Similar results were observed 
for women not vaccinated the previous season. When we combined data for both strata and 
all seasons, aORs in each risk window were <1.0 with relatively narrow 95% confidence 
intervals. Similarly, when we analyzed the data based on number of days between 
conception and vaccination, aORs with all seasons combined were less than or close to 1.0 
in the four risk windows (range 0.5 to 1.1) regardless of whether women were vaccinated the 
previous season or not. A number of our aOR estimates were less than 1.0, although in 
nearly all cases the 95% CI included 1.0. Other influenza vaccine studies have also reported 
risk estimates less than 1.0 for various pregnancy outcomes [17,39,40]. However, 
methodological limitations and residual bias are considered more likely explanations than an 
actual protective effect [41,42].
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The design and implementation of IIV-SAB-3 was similar to the previous two VSD studies, 
with several key differences: (1) we matched subjects on influenza vaccination status in the 
previous season and sampled to ensure approximately equal distribution of subjects by 
previous season vaccination status; (2) we used three more recent influenza seasons; (3) we 
matched cases and controls on three age groups (18–24, 25–34, 35–44 years) rather than two 
(<30 and ≥ 30 years); and (4) the study population was approximately three times larger than 
IIV-SAB-2, permitting more precise estimates for individual seasons and for women 
stratified by previous season vaccination.
Characteristics of the IIV-SAB-3 study population are similar to those of the previous two 
studies (Supplemental Table 11). Women in IIV-SAB-3 were somewhat older than those in 
the previous two studies, and the proportion of women with a history of one or more births 
(parity) was greater than that observed in IIV-SAB-2, but similar to IIV-SAB-1. Median 
gestational age at the time of SAB in IIV-SAB-3 was 7 weeks, which was nearly identical to 
the previous studies [19,20]. The distribution of gestational age at SAB for women in IIV-
SAB-2 and IIV-SAB-3 was similar (Supplemental Fig. 1), although a greater proportion of 
women in IIV-SAB-2 had a SAB at six weeks.
Early studies of influenza vaccine safety in pregnant women did not report any unexpected 
or concerning findings. However, between 1997 and 2004 only women in the second and 
third trimesters were advised to be vaccinated for influenza [9,43,44] resulting in limited 
information on exposures and outcomes like SAB in the first trimester [7,8,10,11,20,45,46]. 
More recently, studies and systematic reviews investigating pH1N1-containing vaccines 
have not identified excess risks of adverse events [3,12,13,15,18,40,47–49]. Overall, 
evidence to support the safety of influenza vaccine in pregnant women is substantial.
A strength of our investigation is the large study population; the total number of case-control 
pairs in the primary analysis (n = 1236) makes it one of the largest case-control studies of 
the association between IIV and SAB reported. Also, as in the previous two VSD studies, we 
abstracted medical records for all cases and controls to collect information on the pregnancy 
and to estimate the date of SAB (more than 2700 records were reviewed). We closely 
matched cases and controls on LMP to ensure that they were in a similar stage of pregnancy; 
the mean pair-wise difference in LMP was zero. Finally, the study population is 
demographically and geographically diverse; the combined membership of the healthcare 
organizations in VSD represents ~3% of the U.S. population [21].
This study has a number of limitations. A difficulty common to all studies of spontaneous 
abortion is estimation of the SAB date. We attempted to estimate the date of pregnancy loss 
when possible and relied on an algorithm developed and refined in the previous two 
studies[19,20], as well as guidance from an obstetrician to integrate various types of 
information from the medical record, such as ultrasound results, clinical and laboratory 
findings, and provider notes. We estimated SAB dates without knowledge of vaccination 
status, so any misclassification should be unrelated to exposure status. Misclassification of 
vaccination status is possible, particularly for women who appeared to be unvaccinated, 
since influenza vaccination is commonly available outside of healthcare systems. However, 
given the strong recommendations for vaccination of pregnant women, we expect that out-
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of-system vaccinations would be documented by the provider in the medical record. Finally, 
women in our study were members of their respective healthcare organization for at least 20 
months prior to their LMP and may not be representative of all pregnant women.
In the context of safety, the results of this study lend support to the ACIP recommendation 
for IIV at any time during pregnancy. We found no clear evidence of an association between 
IIV and SAB; reasons for the apparent discrepancy between IIV-SAB-2 and IIV-SAB-3 are 
unknown. We cannot rule out residual confounding or random error to explain the results of 
IIV-SAB-2; however, differences in the time periods studied might also be relevant. The 
current investigation included three seasons that were further removed from the 2009 
influenza pandemic, while IIV-SAB-2 evaluated the two seasons immediately after the 
pandemic. While the challenges and risks associated with influenza pandemics may be very 
different compared to those observed in seasonal epidemics, assessment of influenza-related 
morbidity and vaccine safety in both settings should include maternal and pregnancy related 
outcomes.
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Fig. 1. 
Identification and confirmation of spontaneous abortions.
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ce
pt
io
n 
w
as
 d
ef
in
ed
 a
s t
he
 d
at
e 
of
 th
e 
la
st 
m
en
str
ua
l p
er
io
d 
pl
us
 1
4 
da
ys
.
b T
he
 re
fe
re
nt
 ex
po
su
re
 g
ro
up
 in
 a
ll 
od
ds
 ra
tio
 c
al
cu
la
tio
ns
 w
as
 c
o
m
pr
ise
d 
of
 w
o
m
en
 u
nv
ac
ci
na
te
d 
as
 o
f t
he
 re
fe
re
nc
e 
da
te
. N
um
be
rs
 in
 p
ar
en
th
es
es
 re
pr
es
en
t 9
5%
 co
nf
id
en
ce
 in
te
rv
al
s. 
G
es
ta
tio
na
l a
ge
 o
f 
ca
se
s 
ra
n
ge
s f
ro
m
 6
 to
 <
20
 w
ee
ks
. B
as
ed
 o
n 
th
e s
et
s o
f c
ov
ar
ia
te
s i
nc
lu
de
d 
in
 st
ra
tu
m
-s
pe
ci
fic
 m
od
el
s, 
th
er
e 
w
er
e 
2 
di
sc
or
da
nt
 p
ai
rs
 w
ith
 m
iss
in
g 
va
lu
es
 fo
r >
1 
co
v
ar
ia
te
 (f
or 
eit
he
r t
he
 ca
se 
or 
co
ntr
ol 
in 
the
 
pa
ir)
 am
on
g w
o
m
en
 v
ac
ci
na
te
d 
in
 th
e 
pr
ev
io
us
 se
as
on
; t
he
re
 w
er
e 
4 
am
on
g 
w
o
m
en
 n
o
t v
ac
ci
na
te
d 
in
 th
e 
pr
ev
io
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 se
as
on
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c D
isc
or
da
nt
 p
ai
rs
: t
he
 fi
rs
t n
um
be
r i
s t
he
 n
um
be
r o
f m
at
ch
ed
 p
ai
rs
 w
he
re
 th
e 
ca
se
 w
as
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ac
ci
na
te
d 
in
 th
e 
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v
an
t e
x
po
su
re
 w
in
do
w
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n
d 
th
e 
co
nt
ro
l w
as
 u
nv
ac
ci
na
te
d 
as
 o
f t
he
 re
fe
re
nc
e 
da
te
, t
he
 se
co
nd
 
n
u
m
be
r i
s t
he
 n
um
be
r o
f m
at
ch
ed
 p
ai
rs
 w
he
re
 th
e 
co
nt
ro
l w
as
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ac
ci
na
te
d 
in
 th
e 
w
in
do
w
 a
n
d 
th
e 
ca
se
 w
as
 u
nv
ac
ci
na
te
d 
as
 o
f t
he
 re
fe
re
nc
e 
da
te
.
d C
ru
de
 o
dd
s r
at
io
s a
re
 c
on
tro
lle
d 
fo
r m
at
ch
in
g 
va
ria
bl
es
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SD
 si
te
, L
M
P,
 
v
ac
ci
na
tio
n 
in
 p
re
v
io
us
 se
as
on
, a
nd
 a
ge
 g
ro
up
 (1
8–
24
, 2
5–
34
, a
nd
 35
–4
4).
e I
n 
ad
di
tio
n 
to
 th
e 
m
at
ch
in
g 
va
ria
bl
es
, a
dju
ste
d o
dd
s r
ati
os 
(aO
R)
 ar
e a
dju
ste
d i
n a
ll m
od
els
 fo
r m
ate
rna
l a
ge
, B
MI
, se
lec
ted
 ra
ce 
va
ria
bl
es
, H
isp
an
ic
 e
th
ni
ci
ty
,
 
an
d 
he
al
th
 c
ar
e 
ut
ili
za
tio
n.
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el
s f
or
 th
e 
st
ra
tu
m
, v
ac
ci
na
te
d 
in
 p
rio
r s
ea
so
n 
= 
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s,
 a
lso
 a
dju
ste
d f
or 
dia
be
tes
, a
sth
ma
, a
nd
 fe
bri
le 
illn
ess
 in
 th
e 1
4 d
ay
s b
efo
re 
the
 re
fer
en
ce 
da
te.
 M
od
els
 fo
r th
e s
tra
tum
, v
ac
ci
na
te
d 
in
 p
rio
r s
ea
so
n 
= 
N
o,
 a
lso
 
ad
jus
ted
 pa
rity
.
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